Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.

Pharmacogenomics - 1 Jan 2014

Lima Aurea, Sousa Hugo, Monteiro Joaquim, Azevedo Rita, Medeiros Rui, Seabra Vitor

Abstract excerpt

Methotrexate (MTX) is used in low doses to treat a variety of diseases. Although the mechanism responsible for its therapeutic action is unknown, MTX membrane transport proteins (influx and/or efflux) can be major determinants of pharmacokinetics, adverse drug reactions and clinical response profiles. With progess in pharmacogenomics, the improvement of the prediction of patients' therapeutic outcome treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP-Binding Cassette Transporters
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Membrane Transport Proteins

Share to Methotrexate

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 25340735
DOI: 10.2217/pgs.14.116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.PMID 25340735Read ↗

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Semantic proximity Read ↗

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is PromisingSemantic proximity Read ↗

Advances in individual prediction of methotrexate toxicity: a reviewSemantic proximity Read ↗

GENETIC PREDICTORS OF TOXIC EFFECTS OF METHOTREXATE IN CANCER PATIENTS.Semantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases.Semantic proximity Read ↗

Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Semantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.